Adzynma (ADAMTS13 recombinant-krhn) — Medica

Initial criteria

• At baseline (prior to therapy) ADAMTS13 activity is < 10% (< 10 IU/dL) [documentation required]
• Patient does not have anti-ADAMTS13 autoantibodies as determined by a diagnostic test [documentation required]
• Patient has a pathogenic variant or a mutation in the ADAMTS13 gene [documentation required]
• Medication is prescribed by or in consultation with a hematologist

Approval duration

1 year